secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2026-07-13T22:11:32+00:00
Accession:  0001185185-26-002922
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Pharma updates investor presentation: Phase 2 CALMA trial >80% enrolled, interim data show agitation reduction
--------------------------------------------------------------------------------

- Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.
- Blinded pooled data (n=107) show LS mean CMAI change of -13.6 at week 2 and -14.9 at week 6 from baseline.
- Interim analysis (n=26) showed IGC-AD1 numerically earlier and larger CMAI reduction vs published brexpiprazole data.
- Sleep disturbance reduced 71% at week 2 (p=0.012) and 78% at EOT (p=0.02) in interim analysis.
- Current market cap ~$30M; presentation outlines potential valuation inflection to $350M-$750M post positive Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/0001185185-26-002922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igc8k071326.htm
  HTML page:      https://secwatch.observer/filing/0001185185-26-002922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer